This enduring activity will uncover the impact of shared decision making (SDM) on optimizing treatment decisions to achieve desired treatment targets in patients with rheumatoid arthritis (RA). Two fast-paced presentations will spotlight the strategy around SDM, including techniques to increase patient engagement and translating clinical trial evidence into good patient decisions. Next, leading faculty will be joined by a patient-actor to stage patient-provider communication inspired by real-life scenarios. The activity will conclude with a roundtable discussion on patient-centered, team-based RA care. Participants will have access to option table decision aids and other resources. This activity is based on the recorded live activity that was conducted in conjunction with the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.
The target audience for this initiative is rheumatologists and members of their healthcare team. Other healthcare professionals who treat patients with RA may also benefit from participation.
Upon completion of the activity, participants should be able to:
Utilize best available evidence for choosing and adjusting DMARD therapy to achieve desired treatment targets in patients with RA.
Effectively engage a patient with RA to make a shared decision about intensifying their DMARD therapy to attain tighter disease control.
Explore best practices for providing team-based care for patients with RA.
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Richard Martin, MD, MA Professor of Medicine and Rheumatology, Michigan State University College of Human Medicine East Lansing, Michigan
Dr. Martin has provided educational consultation for AbbVie; he has contracted research for Lilly, AbbVie, Amgen, AstraZeneca, and BI.
Sheetal Desai, MD, MSEd Chief of Rheumatology, Rheumatology Fellowship Program Director, Director, Lupus Clinic Associate Clinical Professor of Medicine, Division of Rheumatology University of California, Irvine Irvine, California
Dr. Desai has participated in a speaker’s bureau for Janssen Biotech.
Linda Grinnell-Merrick, MS, NP-BC Nurse Practitioner, Division of Allergy, Immunology, and Rheumatology University of Rochester Medical Center Clinical Associate, University of Rochester School of Nursing President of The Rheumatology Nurses Society Rochester, New York
Ms. Grinnell-Merrick has been on an advisory board for: AbbVie, Novartis, Pfizer, and Horizon; she has participated in a speaker’s bureau for: AbbVie, Celgene, Novartis, Janssen; she has also contracted research for Novartis.
Accredited Provider Disclosure
Forefront Collaborative Sydney Pate has nothing to disclose in regards to financial relationship(s) with commercial interests. Marianna Shershneva, MD, PhD, has nothing to disclose in regards to financial relationship(s) with commercial interests.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This continuing medical education activity may include references to unlabeled or unapproved uses of drugs.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
To obtain credit, a score of 80% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.